##### Table of Contents



U.S. SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549
 FORM 10-QSB/A
 QUARTERLY REPORT FOR THE QUARTERLY PERIOD
ENDED MARCH 31, 2007
 COMMISSION FILE NO. 0-28077
 GENELINK, INC.
  PENNSYLVANIA
    
    23-2795613(State or other jurisdiction of 
incorporation or organization
    
    (I.R.S. Employer
Identification No.)Newport Financial Center 
113 Pavonia Avenue, #313Jersey City, NJ
    
    07310(Address of principal executive offices)
  þ o
 o þ
  Number of Shares of Common Stock Outstanding on May 1, 2007
    
    44,104,945
 o þ




---



##### 



EXPLANATORY NOTE
     Page No.PART I.
    
    FINANCIAL INFORMATIONITEM 1.
    
    Financial Statements.Consolidated Balance Sheets at March 31, 2007 (unaudited) and December 31, 2006
    
    
    3Consolidated Statements of Operations for the three months ended March 31, 2007 and 2006 (unaudited)
    
    
    4Consolidated Statements of Cash Flows for the three months ended March 31, 2007 and 2006 (unaudited)
    
    
    5-6Notes to Interim Consolidated Financial Statements
    
    
    7-8Certificate of the Acting Chief Executive Officer and Acting Chief Financial OfficerCertification pursuant to 18 U.S.C. Section 1350
  -2-




---



##### Table of Contents



GENELINK, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
 (Unaudited)March 31,
    
    December 31,2007
    
    2006ASSETSCash and cash equivalents
    
    $
    82,010
    
    
    $
    149,695Accounts receivable
    
    
    31,351
    
    
    
    32,185Inventory
    
    
    4,959
    
    
    
    5,772Prepaid expenses
    
    
    11,273
    
    
    
    14,421Total current assets
    
    
    129,593
    
    
    
    202,073Property and equipment
    
    
    122,313
    
    
    
    131,645Other assets
    
    
    373,263
    
    
    
    380,675Total assets
    
    $
    625,169
    
    
    $
    714,393LIABILITIESAccounts payable and accrued expenses
    
    $
    359,447
    
    
    $
    365,590Loans payable to officers
    
    
    18,000
    
    
    
    18,000Total current liabilities
    
    
    377,447
    
    
    
    383,590Convertible secured promissory notes payable
    
    
    766,312
    
    
    
    622,890Accrued compensation
    
    
    753,023
    
    
    
    725,804Total liabilities
    
    
    1,896,782
    
    
    
    1,732,284SHAREHOLDERS EQUITY (DEFICIENCY)Common stock, $.01 par value, 125,000,000 and 75,000,000
shares authorized as of March 31, 2007 and December 31,
2006, respectively, 44,436,613 and 41,738,988 shares
issued, 44,030,444 and 41,332,819 outstanding as of March
31, 2007 and December 31, 2006, respectively
    
    
    444,367
    
    
    
    417,390Additional paid in capital
    
    
    7,057,943
    
    
    
    6,982,849Stock warrants
    
    
    3,015,009
    
    
    
    3,011,009Accumulated deficit
    
    
    (11,473,877
    )
    
    
    (11,114,084
    )Treasury stock, 406,169 shares as of March 31, 2007 and
December 31, 2006, at cost
    
    
    (315,055
    )
    
    
    (315,055
    )Total shareholders equity (deficiency)
    
    
    (1,271,613
    )
    
    
    (1,017,891
    )Total liabilities and shareholders equity
(deficiency)
    
    $
    625,169
    
    
    $
    714,393
 The accompanying notes are an integral part of the consolidated financial statements
 -3-




---



##### Table of Contents



GENELINK, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
 Three months ended March 31,
    
    2007
    
    2006REVENUE
    
    $
    31,385
    
    
    $
    47,711COSTS OF GOODS SOLD
    
    
    25,123
    
    
    
    16,749GROSS PROFIT
    
    
    6,262
    
    
    
    30,962EXPENSESSelling, general and administrative
    
    
    151,883
    
    
    
    106,432Consulting
    
    
    31,648
    
    
    
    49,320Professional fees
    
    
    164,115
    
    
    
    86,600Advertising and promotion
    
    
    4,234
    
    
    
    5,249Amortization and depreciation
    
    
    14,174
    
    
    
    12,852366,054
    
    
    
    260,453NET LOSS BEFORE PROVISION FOR INCOME TAXES
    
    
    (359,792
    )
    
    
    (229,491
    )PROVISION FOR INCOME TAXES
    
    
    0
    
    
    
    0NET LOSS
    
    $
    (359,792
    )
    
    $
    (229,491
    )NET LOSS PER SHARE, BASIC & DILUTED
    
    $
    (0.01
    )
    
    $
    (0.01
    )Weighted average common shares and diluted
potential common shares
    
    
    42,256,942
    
    
    
    36,777,316
 The accompanying notes are an integral part of the consolidated financial statements.
 -4-




---



##### Table of Contents



GENELINK, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
 Three months ended March 31,
    
    2007
    
    2006CASH FLOWS FROM OPERATING ACTIVITIESNet loss
    
    $
    (359,792
    )
    
    $
    (229,491
    )Adjustments to reconcile net loss to net cash used in
operating activitiesDepreciation and amortization
    
    
    14,174
    
    
    
    12,852Amortization of discounts on loans payable
    
    
    31,324
    
    
    
    5,480Changes in operating assets and liabilitiesAccounts receivable
    
    
    834
    
    
    
    (17,927
    )Inventory
    
    
    813
    
    
    
    1,184Prepaid expenses
    
    
    3,148
    
    
    
    7,580Accounts payable and accrued expenses
    
    
    3,410
    
    
    
    20,770Accrued payroll taxes
    
    
    0
    
    
    
    (112
    )Accrued compensation
    
    
    27,219
    
    
    
    29,231Net cash used in operating activities
    
    
    (278,870
    )
    
    
    (170,433
    )CASH FLOWS FROM INVESTING ACTIVITIESCapital expenditures
    
    
    0
    
    
    
    (11,237
    )Patent acquisition costs
    
    
    (17,215
    )
    
    
    (11,025
    )Net cash used in investing activities
    
    
    (17,215
    )
    
    
    (22,262
    )CASH FLOWS FROM FINANCING ACTIVITIESProceeds from loans and note payable
    
    
    228,400
    
    
    
    183,440Repayment of loan payable
    
    
    0
    
    
    
    (17,861
    )Proceeds relating to issuance of common stock, net
    
    
    0
    
    
    
    24,560Net cash provided by financing activities
    
    
    228,400
    
    
    
    190,139
 The accompanying notes are an integral part of the consolidated financial statements.
 -5-




---



##### Table of Contents



GENELINK, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
 Three months ended March 31,
    
    2007
    
    2006NET DECREASE IN CASH AND
CASH EQUIVALENTS
    
    $
    (67,685
    )
    
    $
    (2,556
    )Cash and cash equivalents, beginning of period
    
    
    149,695
    
    
    
    15,275Cash and cash equivalents, end of period
    
    $
    82,010
    
    
    $
    12,719SUPPLEMENTARY CASH FLOW INFORMATIONCash paid for interest
    
    $
    0
    
    
    $
    265Non-cash financing transactions:Common stock issued for fund raising
    
    $
    1,500
    
    
    $
    0Stock warrants granted for fundraising
    
    $
    4,000
    
    
    $
    0Conversion
of notes payable and accrued interest to common stock
    
    $
    121,131
    
    
    $
    0
 The accompanying notes are an integral part of the consolidated financial statements.
 -6-




---



##### Table of Contents



GENELINK, INC. AND SUBSIDIARY
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
  1  
    
    DESCRIPTION OFORGANIZATION
 Organization
    -7-




---



##### Table of Contents



GENELINK, INC. AND SUBSIDIARY
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
  2  
    
    BASIS OFPRESENTATION
 
   3 
    
    RELATED PARTYTRANSACTIONSAND CONVERTIBLESECUREDPROMISSORY NOTES
 
    -8-




---



ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
   LIQUIDITY AND CAPITAL RESOURCES
     -9-




---



##### Table of Contents



COMPARISON OF THREE MONTHS ENDED MARCH 31, 2007 TO THREE MONTHS ENDED MARCH 31, 2006
 Financial Condition
   Current Year Performance and Earnings Outlook
 Revenues
 Expenses
 Losses
 -10-




---



##### Table of Contents



FACTORS AFFECTING THE COMPANYS BUSINESS AND PROSPECTS
  ITEM 3. CONTROLS AND PROCEDURES.
 Evaluation of Disclosure Controls and Procedures
   Change In Internal Controls
  PART II. OTHER INFORMATION
 Submission of Matters to a Vote of Security Holders
  -11-




---



##### Table of Contents



Nominee
    
    Votes For
    
    Votes WithheldRobert Hoekstra
    
    
    32,788,148
    
    
    
    5,096,831Dr. Bernard L. Kasten, Jr.
    
    
    32,793,148
    
    
    
    5,091,831Robert P. Ricciardi, Ph.D.
    
    
    32,792,648
    
    
    
    5,092,331John H. Souza
    
    
    32,787,648
    
    
    
    5,097,331Monte E. Taylor, Jr.
    
    
    32,792,048
    
    
    
    5,092,931
  Votes For
    
    Votes Against
    
    Abstain32,724,248
    
    
    5,160,631
    
    
    
    0
  Votes For
    
    Votes Against
    
    Abstain24,159,008
    
    
    5,146,331
    
    
    
    200
  (a)
    
    Exhibit No.
 31.1
    
    Certificate of the Acting Chief Executive Officer and Acting
Chief Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.32.1
    
    Certification pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 (b)
    
    Reports on Form 8-K
     -12-




---



##### Table of Contents



GENELINK, INC.
(Registrant)Date:  October 15, 2007
    By:
    /s/ Monte E. Taylor, Jr.Monte E. Taylor, Jr.,Chief Executive Officer andActing Chief Financial Officer -13-